Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT02411786 Completed - Prostate Cancer Clinical Trials

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Start date: August 24, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if a vaccine called pTVG-AR can enhance the participant's immune response against prostate cancer.

NCT ID: NCT02410044 Completed - Breast Cancer Clinical Trials

Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer

PROBone
Start date: December 23, 2014
Phase:
Study type: Observational

Evaluation of patient reported outcomes (PRO) / QoL regarding typical ailments in real-life patients with bone metastases treated with osteoprotective agents.

NCT ID: NCT02409212 Completed - Prostate Cancer Clinical Trials

Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer

PANTERA
Start date: May 2015
Phase: Phase 2
Study type: Interventional

Study design: The study is a two arm randomised controlled trial (randomisation ratio 1:1) comparing an aerobic exercise training intervention to usual care plus exercise advice. The primary outcome is the feasibility of the intervention as novel primary therapy in men with localised prostate cancer.

NCT ID: NCT02407054 Completed - Clinical trials for Prostate Cancer Metastatic

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

Start date: April 29, 2015
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.

NCT ID: NCT02405858 Completed - Clinical trials for Metastatic Castration-Resistant Prostate Cancer

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Start date: April 10, 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the percentage of participants achieving prostate-specific antigen (PSA) response by 12 weeks of therapy from baseline according to Prostate Cancer Clinical Trials Working Group (PCWG2) criteria.

NCT ID: NCT02398526 Completed - Clinical trials for Castration-Resistant Prostatic Cancer

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

PARABO
Start date: March 19, 2015
Phase:
Study type: Observational

This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.

NCT ID: NCT02397629 Completed - Prostate Cancer Clinical Trials

Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis

Start date: May 2013
Phase:
Study type: Observational

This is a cross sectional study to examine the relationship between serum calcium and PTHrP and serum PSA in men referred for prostate biopsy at Wake Forest University.

NCT ID: NCT02397408 Completed - Prostate Cancer Clinical Trials

11C- and 18F-Choline PET/MR Imaging for Prostate Cancer

Start date: April 9, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well 11C-choline (carbon C 11 choline) and 18F-choline (fluorine F 18 choline) positron emission tomography/magnetic resonance (PET/MR) imaging works in diagnosing patients with unfavorable intermediate to high-risk prostate cancer. Diagnostic procedures, such as 11C- and 18F-choline PET/MR may help find and diagnose prostate cancer and find out how far the disease has spread.

NCT ID: NCT02394223 Completed - Clinical trials for Patients With PSA Level 4.0 ng/mL

FFOCT for the Diagnosis of Prostate Cancer

BIOMAGIC01
Start date: January 27, 2016
Phase:
Study type: Observational

Primary objective : The primary objective is to evaluate the diagnosis performance of FFOCT for cancer detection in patients undergoing TRUS prostate biopsy, as compared to standard pathological evaluation. Secondary objective: - Evaluate predictive values of FFOCT for cancer detection on prostate biopsy cores - Evaluate the value of FFOCT for cancer characterization on prostate biopsy cores - Evaluate the reproducibility of FFOCT evaluation for cancer detection on prostate biopsy cores - Evaluate the learning curve of FFOCT evaluation on prostate biopsy cores - Evaluate FFOCT procedure time

NCT ID: NCT02391025 Completed - Prostatic Neoplasms Clinical Trials

Gallium-68 Citrate PET Used in Prostate Cancer

Start date: May 28, 2015
Phase: Early Phase 1
Study type: Interventional

This is a single center, pilot, cross-sectional imaging study investigating the use of gallium-68 citrate PET in participants with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will consist of participants with metastatic castration-resistant prostate cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001 (CC#125519), with evidence of resistance to androgen signaling inhibition.